LGG-Avastin: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab (Avastin) for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma

Avastin is a drug that is approved for use in some adult cancers. This study will assess the effectiveness of adding Avastin to the standard chemotherapy treatment for low grade glioma (LGG) in children and adolescents. The child or adolescent will be randomly allocated to receive standard treatment with or without Avastin. It will determine whether Avastin is a safe and effective treatment to slow tumour growth.

Disease Stage: Unresectable or progressive disease

Patient Age Range: 6mths – <18 years

Sample Size: 150

Trial Sponsors:

• International: The Hospital for Sick Children, Toronto
• National: ANZCHOG

Read more at Clinical Trials Registry